Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1989 Sep 1;170(3):827–845. doi: 10.1084/jem.170.3.827

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

PMCID: PMC2189443  PMID: 2504877

Abstract

We have identified and purified a novel cytokine, NK cell stimulatory factor (NKSF), from the cell-free supernatant fluid of the phorbol diester-induced EBV-transformed human B lymphoblastoid cell line RPMI 8866. NKSF activity is mostly associated to a 70-kD anionic glycoprotein. The purified 70-kD protein, isolated from an SDS-PAGE gel, yields upon reduction two small species of molecular masses of 40 and 35 kD, suggesting that this cytokine is a heterodimer. When added to human PBL, purified NKSF preparations induce IFN-gamma production and synergize with rIL-2 in this activity, augment the NK cell-mediated cytotoxicity of PBL preparations against both NK-sensitive and NK- resistant target cell lines, and enhance the mitogenic response of T cells to mitogenic lectins and phorbol diesters. The three activities remain associated through different purification steps resulting in a 9,200-fold purification, and purified NKSF mediates the three biological activities at concentrations in the range of 0.1-10 pM. These data strongly suggest that the same molecule mediates these three activities, although the presence of traces of contaminant peptides even in the most purified NKSF preparations does not allow us to exclude the possibility that distinct biologically active molecules have been co-purified. The absence of other known cytokines in the purified NKSF preparations, the unusual molecular conformation of NKSF, the high specific activity of the purified protein, and the spectrum of biological activities distinguish NKSF from other previously described cytokines.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrus J. L., Jr, Jurgensen C. H., Brown E. J., Fauci A. S. Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor. J Exp Med. 1985 Oct 1;162(4):1319–1335. doi: 10.1084/jem.162.4.1319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antonelli G., Blalock J. E., Dianzani F. Generation of a soluble IFN-gamma inducer by oxidation of galactose residues on macrophages. Cell Immunol. 1985 Sep;94(2):440–446. doi: 10.1016/0008-8749(85)90268-0. [DOI] [PubMed] [Google Scholar]
  3. Antonelli G., Dianzani F., Van Damme J., Amicucci P., De Marco F., Cefaro A. A macrophage-derived factor different from interleukin 1 and able to induce interferon-gamma and lymphoproliferation in resting T lymphocytes. Cell Immunol. 1988 May;113(2):376–386. doi: 10.1016/0008-8749(88)90035-4. [DOI] [PubMed] [Google Scholar]
  4. Cuturi M. C., Anegón I., Sherman F., Loudon R., Clark S. C., Perussia B., Trinchieri G. Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med. 1989 Feb 1;169(2):569–583. doi: 10.1084/jem.169.2.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cuturi M. C., Murphy M., Costa-Giomi M. P., Weinmann R., Perussia B., Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med. 1987 Jun 1;165(6):1581–1594. doi: 10.1084/jem.165.6.1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elias J. A., Trinchieri G., Beck J. M., Simon P. L., Sehgal P. B., May L. T., Kern J. A. A synergistic interaction of IL-6 and IL-1 mediates the thymocyte-stimulating activity produced by recombinant IL-1-stimulated fibroblasts. J Immunol. 1989 Jan 15;142(2):509–514. [PubMed] [Google Scholar]
  7. Garman R. D., Jacobs K. A., Clark S. C., Raulet D. H. B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7629–7633. doi: 10.1073/pnas.84.21.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  10. Hercend T., Meuer S., Reinherz E. L., Schlossman S. F., Ritz J. Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol. 1982 Sep;129(3):1299–1305. [PubMed] [Google Scholar]
  11. Itoh K., Shiiba K., Shimizu Y., Suzuki R., Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J Immunol. 1985 May;134(5):3124–3129. [PubMed] [Google Scholar]
  12. Jensen J. R., Sand T. T., Spiegelberg H. L. Generation of IgE-binding and IgG-binding factors from human lymphoblastoid cell lines. Immunology. 1984 Sep;53(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  13. Kehrl J. H., Dukovich M., Whalen G., Katz P., Fauci A. S., Greene W. C. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. J Clin Invest. 1988 Jan;81(1):200–205. doi: 10.1172/JCI113295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klein G., Vilcek J. Attempts to induce interferon production by IdUrd induction and EBV superinfection in human lymphoma lines and their hybrids. J Gen Virol. 1980 Jan;46(1):111–117. doi: 10.1099/0022-1317-46-1-111. [DOI] [PubMed] [Google Scholar]
  15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  16. Landolfo S., Cofano F., Giovarelli M., Prat M., Cavallo G., Forni G. Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science. 1985 Jul 12;229(4709):176–179. doi: 10.1126/science.3160110. [DOI] [PubMed] [Google Scholar]
  17. London L., Perussia B., Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol. 1986 Dec 15;137(12):3845–3854. [PubMed] [Google Scholar]
  18. London L., Perussia B., Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: expression of surface activation antigens. J Immunol. 1985 Feb;134(2):718–727. [PubMed] [Google Scholar]
  19. Michael A., Hackett J. J., Bennett M., Kumar V., Yuan D. Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma. J Immunol. 1989 Feb 15;142(4):1095–1101. [PubMed] [Google Scholar]
  20. Mond J. J., Brunswick M. A role for IFN-gamma and NK cells in immune responses to T cell-regulated antigens types 1 and 2. Immunol Rev. 1987 Oct;99:105–118. doi: 10.1111/j.1600-065x.1987.tb01174.x. [DOI] [PubMed] [Google Scholar]
  21. Muraguchi A., Kishimoto T., Miki Y., Kuritani T., Kaieda T., Yoshizaki K., Yamamura Y. T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol. 1981 Aug;127(2):412–416. [PubMed] [Google Scholar]
  22. Ortaldo J. R., Mason A. T., Gerard J. P., Henderson L. E., Farrar W., Hopkins R. F., 3rd, Herberman R. B., Rabin H. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol. 1984 Aug;133(2):779–783. [PubMed] [Google Scholar]
  23. Ostensen M. E., Thiele D. L., Lipsky P. E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol. 1987 Jun 15;138(12):4185–4191. [PubMed] [Google Scholar]
  24. Perussia B., Mangoni L., Engers H. D., Trinchieri G. Interferon production by human and murine lymphocytes in response to alloantigens. J Immunol. 1980 Oct;125(4):1589–1595. [PubMed] [Google Scholar]
  25. Perussia B., Ramoni C., Anegon I., Cuturi M. C., Faust J., Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6(4):171–188. [PubMed] [Google Scholar]
  26. Phillips J. H., Le A. M., Lanier L. L. Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens. J Exp Med. 1984 Apr 1;159(4):993–1008. doi: 10.1084/jem.159.4.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Reem G. H., Cook L. A., Henriksen D. M., Vilcek J. Gamma interferon induction in human thymocytes activated by lectins and B cell lines. Infect Immun. 1982 Jul;37(1):216–221. doi: 10.1128/iai.37.1.216-221.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985 Oct;75(4):595–603. [PubMed] [Google Scholar]
  29. Scala G., Kuang Y. D., Hall R. E., Muchmore A. V., Oppenheim J. J. Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line. J Exp Med. 1984 Jun 1;159(6):1637–1652. doi: 10.1084/jem.159.6.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Trinchieri G., De Marchi M., Mayr W., Savi M., Ceppellini R. Lymphocyte antibody lymphocytolytic interaction (LALI) with special emphasis on HL-A. Transplant Proc. 1973 Dec;5(4):1631–1649. [PubMed] [Google Scholar]
  31. Trinchieri G., Kobayashi M., Rosen M., Loudon R., Murphy M., Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 1986 Oct 1;164(4):1206–1225. doi: 10.1084/jem.164.4.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984 Oct 1;160(4):1147–1169. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med. 1978 May 1;147(5):1314–1333. doi: 10.1084/jem.147.5.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wilson A. B., Harris J. M., Coombs R. R. Interleukin-2-induced production of interferon-gamma by resting human T cells and large granular lymphocytes: requirement for accessory cell factors, including interleukin-1. Cell Immunol. 1988 Apr 15;113(1):130–142. doi: 10.1016/0008-8749(88)90012-3. [DOI] [PubMed] [Google Scholar]
  35. Yamamoto R. S., Johnson D. L., Masunaka I. K., Granger G. A. Phorbol myristate acetate induction of lymphotoxins from continuous human B lymphoid cell lines in vitro. J Biol Response Mod. 1984;3(1):76–87. [PubMed] [Google Scholar]
  36. Ythier A., Delmon L., Reinherz E., Nowill A., Moingeon P., Mishal Z., Bohuon C., Hercend T. Proliferative responses of circulating human NK cells: delineation of a unique pathway involving both direct and helper signals. Eur J Immunol. 1985 Dec;15(12):1209–1215. doi: 10.1002/eji.1830151213. [DOI] [PubMed] [Google Scholar]
  37. van de Griend R. J., van Krimpen B. A., Ronteltap C. P., Bolhuis R. L. Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells. J Immunol. 1984 Jun;132(6):3185–3191. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES